ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Drug Approvals: FDA grants accelerated approval for Keytruda in metastatic melanoma

September 5, 2014

AACR Supports Bypass Budget; Public Consortium Sequences Mouse Genome

May 10, 2002

New Center Plan Discussed By NAB, Directors Committees

May 4, 1990

Gonzalez-Angulo Found Guilty in MD Anderson Poisoning Case

September 26, 2014

Three cancer centers joined the Multiple Myeloma Research Consortium.

September 16, 2005

Educational Strategies On Mammography, Not Guidelines, To Come From NCAB

February 28, 1997